Cargando…

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial

OBJECTIVE: To assess associations between the extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial. MATERIAL AND METHODS: We used generalized ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denton, Christopher P, Goh, Nicole S, Humphries, Stephen M, Maher, Toby M, Spiera, Robert, Devaraj, Anand, Ho, Lawrence, Stock, Christian, Erhardt, Elvira, Alves, Margarida, Wells, Athol U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152288/ https://www.ncbi.nlm.nih.gov/pubmed/36111858 http://dx.doi.org/10.1093/rheumatology/keac535

Ejemplares similares

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
por: Maher, Toby M., et al.
Publicado: (2022)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

The role of precision medicine in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease
por: Jacob, Joseph, et al.
Publicado: (2018)

The adoption of nintedanib in systemic sclerosis: the SENSCIS study
por: Bruni, Teresa, et al.
Publicado: (2020)

Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
por: Kreuter, Michael, et al.
Publicado: (2022)

Interstitial Lung Abnormalities: An Evolving Entity
por: Tomassetti, Sara, et al.
Publicado: (2022)

Residual Lung Disease at 6-month Follow-up CT after COVID-19: Clinical Significance Is a Key Issue
por: Wells, Athol U, et al.
Publicado: (2021)

Comorbidities in interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2017)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2019)

Smoking and interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2015)

Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease
por: Lindahl, Gisela E, et al.
Publicado: (2013)

Defining genetic risk factors for scleroderma-associated interstitial lung disease: IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease
por: Stock, Carmel J. W., et al.
Publicado: (2020)

Predicting outcomes in rheumatoid arthritis related interstitial lung disease
por: Jacob, Joseph, et al.
Publicado: (2019)

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
por: Saunders, Peter, et al.
Publicado: (2017)

COVID‐19 related lung pathology: old patterns in new clothing?
por: Nicholson, Andrew G, et al.
Publicado: (2020)

Serial Decline in Lung Volume Parameters on Computed Tomography (CT) Predicts Outcome in Idiopathic Pulmonary Fibrosis (IPF)
por: Robbie, Hasti, et al.
Publicado: (2022)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
por: Khanna, Dinesh, et al.
Publicado: (2015)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
por: Kreuter, Michael, et al.
Publicado: (2022)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”
por: Brown, Kevin K., et al.
Publicado: (2020)

Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges
por: Kewalramani, Namrata, et al.
Publicado: (2022)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
por: Bruni, Cosimo, et al.
Publicado: (2022)

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?
por: Kreuter, Michael, et al.
Publicado: (2022)

Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent
por: Invernizzi, Rachele, et al.
Publicado: (2020)

Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis
por: Gayle, Alicia, et al.
Publicado: (2020)

Evaluation of inter-observer variation for computed tomography identification of childhood interstitial lung disease
por: Jacob, Joseph, et al.
Publicado: (2019)

Short‐term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis
por: Macaluso, Claudio, et al.
Publicado: (2022)

A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease
por: Bax, Simon, et al.
Publicado: (2018)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives
por: Tomassetti, Sara, et al.
Publicado: (2022)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_487q500sq398rpvuekuqcbisf8